122 related articles for article (PubMed ID: 25634447)
21. Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5.
Mouly SJ; Matheny C; Paine MF; Smith G; Lamba J; Lamba V; Pusek SN; Schuetz EG; Stewart PW; Watkins PB
Clin Pharmacol Ther; 2005 Dec; 78(6):605-18. PubMed ID: 16338276
[TBL] [Abstract][Full Text] [Related]
22. Pharmacogenomics as molecular autopsy for forensic toxicology: genotyping cytochrome P450 3A4*1B and 3A5*3 for 25 fentanyl cases.
Jin M; Gock SB; Jannetto PJ; Jentzen JM; Wong SH
J Anal Toxicol; 2005 Oct; 29(7):590-8. PubMed ID: 16419387
[TBL] [Abstract][Full Text] [Related]
23. Inactivation of Human Cytochrome P450 3A4 and 3A5 by Dronedarone and N-Desbutyl Dronedarone.
Hong Y; Chia YM; Yeo RH; Venkatesan G; Koh SK; Chai CL; Zhou L; Kojodjojo P; Chan EC
Mol Pharmacol; 2016 Jan; 89(1):1-13. PubMed ID: 26490246
[TBL] [Abstract][Full Text] [Related]
24. Differences in the inhibition of cytochromes P450 3A4 and 3A5 by metabolite-inhibitor complex-forming drugs.
McConn DJ; Lin YS; Allen K; Kunze KL; Thummel KE
Drug Metab Dispos; 2004 Oct; 32(10):1083-91. PubMed ID: 15377640
[TBL] [Abstract][Full Text] [Related]
25. Association of CYP3A5 Expression and Vincristine Neurotoxicity in Pediatric Malignancies in Turkish Population.
Kayilioğlu H; Kocak U; Kan Karaer D; Percin EF; Sal E; Tekkesin F; Isik M; Oner N; Belen FB; Yilmaz Keskin E; Okur A; Albayrak M; Kaya Z; Pinarli FG; Yenicesu I; Karadeniz C; Oguz A; Gursel T
J Pediatr Hematol Oncol; 2017 Aug; 39(6):458-462. PubMed ID: 28697165
[TBL] [Abstract][Full Text] [Related]
26. The X-Ray Crystal Structure of the Human Mono-Oxygenase Cytochrome P450 3A5-Ritonavir Complex Reveals Active Site Differences between P450s 3A4 and 3A5.
Hsu MH; Savas U; Johnson EF
Mol Pharmacol; 2018 Jan; 93(1):14-24. PubMed ID: 29093019
[TBL] [Abstract][Full Text] [Related]
27. Contribution of cytochrome P450 3A4 and 3A5 to the metabolism of atorvastatin.
Park JE; Kim KB; Bae SK; Moon BS; Liu KH; Shin JG
Xenobiotica; 2008 Sep; 38(9):1240-51. PubMed ID: 18720283
[TBL] [Abstract][Full Text] [Related]
28. Genotype-phenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivo.
He P; Court MH; Greenblatt DJ; Von Moltke LL
Clin Pharmacol Ther; 2005 May; 77(5):373-87. PubMed ID: 15900284
[TBL] [Abstract][Full Text] [Related]
29. Computational Investigation of Ligand Binding to the Peripheral Site in CYP3A4: Conformational Dynamics and Inhibitor Discovery.
Du H; Li J; Cai Y; Zhang H; Liu G; Tang Y; Li W
J Chem Inf Model; 2017 Mar; 57(3):616-626. PubMed ID: 28221037
[TBL] [Abstract][Full Text] [Related]
30. Identification of Potential Cytochrome P450 3A5 Inhibitors: An Extensive Virtual Screening through Molecular Docking, Negative Image-Based Screening, Machine Learning and Molecular Dynamics Simulation Studies.
Islam MA; Dudekula DB; Rallabandi VPS; Srinivasan S; Natarajan S; Chung H; Park J
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012627
[TBL] [Abstract][Full Text] [Related]
31. Structural characterization of the homotropic cooperative binding of azamulin to human cytochrome P450 3A5.
Hsu MH; Johnson EF
J Biol Chem; 2022 May; 298(5):101909. PubMed ID: 35398097
[TBL] [Abstract][Full Text] [Related]
32. Influence of P450 3A4 SRS-2 residues on cooperativity and/or regioselectivity of aflatoxin B(1) oxidation.
Xue L; Wang HF; Wang Q; Szklarz GD; Domanski TL; Halpert JR; Correia MA
Chem Res Toxicol; 2001 May; 14(5):483-91. PubMed ID: 11368545
[TBL] [Abstract][Full Text] [Related]
33. Selective metabolism of vincristine in vitro by CYP3A5.
Dennison JB; Kulanthaivel P; Barbuch RJ; Renbarger JL; Ehlhardt WJ; Hall SD
Drug Metab Dispos; 2006 Aug; 34(8):1317-27. PubMed ID: 16679390
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of human CYP3A4 and CYP3A5 enzymes by gomisin C and gomisin G, two lignan analogs derived from Schisandra chinensis.
Zhao J; Sun T; Wu JJ; Cao YF; Fang ZZ; Sun HZ; Zhu ZT; Yang K; Liu YZ; Gonzalez FJ; Yin J
Fitoterapia; 2017 Jun; 119():26-31. PubMed ID: 28344076
[TBL] [Abstract][Full Text] [Related]
35. Pharmacogenetic determinants of human liver microsomal alfentanil metabolism and the role of cytochrome P450 3A5.
Klees TM; Sheffels P; Thummel KE; Kharasch ED
Anesthesiology; 2005 Mar; 102(3):550-6. PubMed ID: 15731592
[TBL] [Abstract][Full Text] [Related]
36. Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro.
Granfors MT; Wang JS; Kajosaari LI; Laitila J; Neuvonen PJ; Backman JT
Basic Clin Pharmacol Toxicol; 2006 Jan; 98(1):79-85. PubMed ID: 16433896
[TBL] [Abstract][Full Text] [Related]
37. Differential Effects of Clotrimazole on X-Ray Crystal Structures of Human Cytochromes P450 3A5 and 3A4.
Hsu MH; Johnson EF
Drug Metab Dispos; 2023 Dec; 51(12):1642-1650. PubMed ID: 37770228
[TBL] [Abstract][Full Text] [Related]
38. Pi-pi Stacking Mediated Cooperative Mechanism for Human Cytochrome P450 3A4.
Fa B; Cong S; Wang J
Molecules; 2015 Apr; 20(5):7558-73. PubMed ID: 25919277
[TBL] [Abstract][Full Text] [Related]
39. Relative contributions of cytochrome CYP3A4 versus CYP3A5 for CYP3A-cleared drugs assessed in vitro using a CYP3A4-selective inactivator (CYP3cide).
Tseng E; Walsky RL; Luzietti RA; Harris JJ; Kosa RE; Goosen TC; Zientek MA; Obach RS
Drug Metab Dispos; 2014 Jul; 42(7):1163-73. PubMed ID: 24737844
[TBL] [Abstract][Full Text] [Related]
40. Molecular Dynamics Simulation Framework to Probe the Binding Hypothesis of CYP3A4 Inhibitors.
Kiani YS; Ranaghan KE; Jabeen I; Mulholland AJ
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31510073
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]